Profile data is unavailable for this security.
About the company
DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for use by people with diabetes and by healthcare providers. Its Dexcom G6 is a CGM system that can be used as part of an integrated system with other compatible medical devices and electronic interfaces, which may include automated insulin dosing systems, insulin pumps, blood glucose meters or other electronic devices used for diabetes management. Its Dexcom Share remote monitoring system, offered for use with its Dexcom system, uses an application on the patient's mobile device to wirelessly transmit glucose information to the cloud and then to applications on the mobile devices of up to five designated recipients. Its Dexcom Real-Time API enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices. Its other products include Dexcom ONE and Dexcom G7.
- Revenue in USD (TTM)2.79bn
- Net income in USD230.00m
- Incorporated1999
- Employees6.30k
- LocationDexcom Inc6340 Sequence DrSAN DIEGO 92121-4356United StatesUSA
- Phone+1 (858) 200-0200
- Fax+1 (302) 636-5454
- Websitehttps://www.dexcom.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zimmer Biomet Holdings Inc | 7.15bn | 338.40m | 25.02bn | 19.50k | 74.19 | 2.04 | 19.18 | 3.50 | 1.61 | 1.32 | 34.08 | 58.36 | 0.3155 | 0.9301 | 5.36 | 366,805.10 | 1.50 | 1.03 | 1.69 | 1.16 | 69.79 | 71.16 | 4.74 | 3.31 | 1.05 | 7.20 | 0.3181 | 77.35 | 11.56 | 0.4339 | 400.00 | 7.13 | -1.88 | 0.00 |
| Baxter International Inc | 14.74bn | -2.38bn | 28.23bn | 60.00k | -- | 5.10 | -- | 1.92 | -4.72 | -4.72 | 29.10 | 10.98 | 0.6171 | 3.99 | 6.37 | 245,666.70 | -9.90 | 6.03 | -11.66 | 7.22 | 36.38 | 41.58 | -16.04 | 10.02 | 1.38 | 5.22 | 0.7465 | 38.31 | 9.52 | 4.70 | 16.52 | -23.70 | 0.6589 | 16.53 |
| Resmed Inc | 3.62bn | 786.30m | 33.68bn | 8.16k | 43.00 | 9.81 | 35.71 | 9.29 | 5.35 | 5.35 | 24.65 | 23.44 | 0.7317 | 2.28 | 5.82 | 444,167.30 | 15.87 | 13.19 | 18.31 | 15.51 | 56.80 | 57.33 | 21.69 | 18.67 | 1.69 | 18.72 | 0.1881 | 40.45 | 11.93 | 11.60 | 64.26 | 17.89 | 16.90 | 4.94 |
| DexCom, Inc. | 2.79bn | 230.00m | 43.26bn | 6.30k | 209.20 | 23.71 | 113.34 | 15.49 | 0.5354 | 0.5354 | 6.71 | 4.72 | 0.5773 | 2.87 | 5.11 | 443,301.60 | 4.75 | 5.56 | 5.72 | 6.50 | 65.97 | 67.29 | 8.24 | 8.91 | 3.43 | 12.92 | 0.5266 | 0.00 | 27.08 | 33.69 | -68.66 | -- | 47.52 | -- |
| Edwards Lifesciences Corp | 5.36bn | 1.46bn | 47.21bn | 15.70k | 32.87 | 7.61 | 29.58 | 8.80 | 2.32 | 2.32 | 8.54 | 10.04 | 0.6386 | 1.51 | 8.80 | 341,643.30 | 17.37 | 15.99 | 19.56 | 18.95 | 78.93 | 75.11 | 27.20 | 23.63 | 3.00 | -- | 0.0875 | 0.00 | 19.29 | 12.04 | 82.55 | 21.42 | 8.69 | -- |
| Boston Scientific Corporation | 12.57bn | 597.00m | 63.24bn | 41.00k | 106.37 | 3.58 | 36.57 | 5.03 | 0.4151 | 0.4151 | 8.74 | 12.32 | 0.3938 | 2.31 | 7.10 | 306,512.20 | 2.04 | 3.26 | 2.32 | 4.00 | 68.89 | 69.40 | 5.19 | 8.03 | 0.9456 | 6.77 | 0.3273 | 0.00 | 19.92 | 7.23 | 956.52 | 23.20 | 1.75 | -- |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Sep 2022 | 42.06m | 10.89% |
| BlackRock Fund Advisorsas of 30 Sep 2022 | 21.74m | 5.63% |
| Baillie Gifford & Co.as of 30 Sep 2022 | 18.11m | 4.69% |
| Sands Capital Management LLCas of 30 Sep 2022 | 16.69m | 4.32% |
| SSgA Funds Management, Inc.as of 30 Sep 2022 | 16.39m | 4.24% |
| Capital Research & Management Co. (Global Investors)as of 30 Sep 2022 | 10.53m | 2.73% |
| Wellington Management Co. LLPas of 30 Sep 2022 | 9.05m | 2.34% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2022 | 8.98m | 2.32% |
| Geode Capital Management LLCas of 30 Sep 2022 | 8.02m | 2.08% |
| JPMorgan Investment Management, Inc.as of 30 Sep 2022 | 7.25m | 1.88% |
